ESR1 and cancer: Importantly, although they are distinct receptors, estrogen receptor-alpha (ER) and progesterone receptor isoforms (PRs) act either antagonistically or collaboratively, driving proliferation but contributing to cancer stem cell expansion and therapy resistance.